Atlas Trials

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Clinical trial NCT05551598 · COMPLETED

Trial details

NCT number
NCT05551598
Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuromyelitis Optica Spectrum Disorder
Start date
2022-11-28
Primary completion
2024-07-18
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.